Skip to Main Content
CWRU Links

2012 Articles

January 23, 2012

Date Released: 23 January 2012
News Banner


Therapy Can Add Years to Certain Brain Tumor Patients' Lives
USA Today - Jan 23, 2012
Steven Rosenfeld, who directs the brain tumor center at the Cleveland Clinic, has been following the research closely and already tests his patients for the gene abnormalities.

Cardiac Risk Higher for Women Getting Radiation
MedPage Today - Jan 23, 2012
Neal Meropol, MD, a co-author of the study, told MedPage Today that the aim of the retrospective study was hypothesis-generating.

UH Case Medical Center Publishes Study on Novel Treatment for Skin Lymphoma
EurekAlert - Jan 17, 2012
...more effective and less toxic to the skin, allowing for more optimal treatments," says Kevin Cooper, MD, Chairman of the Department of Dermatology at UH Case Medical Center and...


Cancer Center Seminar Series: Experimental Therapeutics: The Chronic B-Cell Leukemias

Dr. Michael R. Grever

Friday, January 27
12 pm
BRB 105

Please join us Friday, January 27 for the next Cancer Center Seminar Series where Dr. Michael R. Grever will present Experimental Therapeutics: The Chronic B-Cell Leukemias.

Dr. Grever has over 30 years of experience in experimental chemotherapy and drug development for patients with CLL and other hematologic malignancies. He previously served as the Deputy Director of the NCI's Division of Cancer Treatment and the Associate Director of the NCI's Developmental Therapeutics Program, directing the preclinical effort for drug discovery and development of anti-cancer and anti-HIV agents. Dr. Grever performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies, and conducted one of the initial phase II studies of fludarabine in patients with CLL.

Dr. Grever remains active in the search for new and effective therapy for CLL. He continues to lead the Phase I Program at OSU, and also provides leadership at a national level, as he recently finished his term as Co-Chair of the NCI's Investigational Drug Branch Steering Committee. He has also served on both RAID and NExT review committees for the NCI. In addition to the U01 funding, he is actively engaged in collaborative team based research involving P01, P50, SPORE, and SCOR projects. His background in pharmacology enabled him to co-lead the program forward with pharmacologically-directed phase I studies of an exciting agent (Flavopiridol). He worked with this agent pre-clinically at the NCI and pursued its clinical development over the past decade. He is now responsible for advising on the preclinical and early clinical development of many new synthetic agents as well as interesting natural products. He has been fortunate to have experience both in preclinical drug discovery and development, as well as the design and conduct of clinical trials leading to FDA approval for several new agents, and shares his experiences with young investigators in his program.

Office of Cancer Centers Learning Series Webinar

Register for the next Office of Cancer Centers Learning Series Webinar, An Overview of the FY 2012 Cancer Clinical Investigator Team Leadership Award Application and Review Process for Prospective ApplicantsWednesday, February 1from 2-3:30 pm.

Dr. Jennifer Hayes, the NCI Program Director who oversees the Cancer Clinical Investigator Team Leadership Award Program, will present an overview of the FY 2012 program and discuss the application and application review process.


Samuel Waxman Cancer Research Foundation: Individual Research Proposals

This year, the Samuel Waxman Cancer Research Foundation (SWCRF) will offer several two-year grants to individual investigators. Grantees will have the opportunity to extend their award to three years upon demonstration of successful collaborative efforts with existing members of the SWCRF Institute Without Walls. This RFA will focus on the pursuit of novel compounds, targets, and therapies.

Specific themes of interest to the SWCRF include studies that address:

  • aberrant gene regulation
  • transcriptional and signal transduction
  • epimutations
  • cell dormancy vs. proliferation

Internal Deadline: February 1
External Deadline: March 15

NSF Integrative Graduate Education and Research Traineeship Program (IGERT)

The Integrative Graduate Education and Research Traineeship (IGERT) program has been developed to meet the challenges of educating U.S. Ph.D. scientists and engineers with interdisciplinary backgrounds, deep knowledge in chosen disciplines, and technical, professional, and personal skills. The program is intended to establish new models for graduate education and training in a fertile environment for collaborative research that transcends traditional disciplinary boundaries.

This is a limited submission opportunity and only 1 application per institution is allowed.

Internal Deadline: February 27

New York Academy of Medicine David E. Rogers Fellowship Program

The Rogers Fellowship is meant to enrich the educational experiences of medical and dental students through projects that bear on medicine and dentistry as they contribute to the health of communities, and to address the human needs of underserved or disadvantaged patients or populations. The content of the Fellowship might include clinical investigation, public health/epidemiology, health policy analysis, activities linking biomedicine, the social infrastructure and human or community need.

Deadline: March 1

American Cancer Society Postdoctoral Fellowships

The American Cancer Society is accepting applications forpostdoctoral fellowships. These awards support the training of researchers who have received a doctoral degree to provide initial funding leading to an independent career in cancer research (including basic, preclinical, clinical, cancer control, psychosocial, behavioral, epidemiology, health services and health policy research).

Deadline: April 2

Solving Kids' Cancer Therapeutic Development Initiative

Solving Kids' Cancer is accepting proposals for itsTherapeutic Development Initiative (TDI), a strategic program to support the investigation of novel treatments through clinical studies to answer important research questions as quickly, effectively, and economically as possible. Ideal proposals will be those that focus on novel and potentially high-impact therapeutic approaches through well designed clinical studies for neuroblastoma, pediatric CNS tumors and/or sarcomas. Proposals will be accepted on a rolling-basis throughout the year.

Support of the Cancer Genome Atlas Program

SAIC-Frederick is pleased to announce a new solicitation available in support of The Cancer Genome Atlas (TCGA) Program. The Cancer Genome Atlas is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. This funding is made available under Congressional appropriated funding and also the American Recovery and Reinvestment Act of 2009 (Recovery Act), Pub. L. No. 111-5.

SAIC Frederick hopes to receive proposals from institutions and established network sites that currently collect high quality biospecimens. TCGA TSS awardees will either have an on-site biorepository (located in the same institution as the specimen collection) or demonstrate capability to collect, short-term store, and ship high quality biospecimens to an appropriate biorepository. SAIC-Frederick is hopeful that many sites will meet the qualifications and would find it attractive to participate in the specimen collection portion of TCGA. Proposals shall continue to be accepted on a rolling basis thereafter until the solicitation is amended and closed.

Case CCC Clinical Trials Protocol Specific Research Support Funding

The Case CCC is encouraging investigators to submit Letters of Intent for the Protocol Specific Research Support funding for Year 2012. The budgeted funds are for the conduct of early phase clinical trials and restricted to support research nurses and data managers directly involved in the conduct of these clinical trials. Studies developed jointly between UH and CCF with planned accrual at both institutions will be prioritized. Please direct questions and requests for information about the funding process to Katarzyna Karelus, Administrative Director, Case CCC Clinical Research Office, at 216.844.4176 or





**All events are open to anyone interested in attending

January 23

Skeletal Research Center Seminar
Hulya Bukulmez, MD
Assistant Professor, Pediatrics
Topic: Anti-Inflammatory Effects of Growth Factors on Cartilage
4 pm Millis 123

January 24

Cancer Biology and Glickman Urological and Kidney Institute: Prostate Cancer Endowed Chair Candidate Seminar
Marianne Sadar, PhD
Senior Scientist, Genome Sciences Centre
Provincial Program Leader, Prostate Cancer Research
British Columbia Cancer Agency
Topic: A New Approach for the Treatment of Prostate Cancer
11 am NC1-202 Cleveland Clinic

Immunology Seminar Series
Gail Bishop, PhD
Professor, Microbiology and Internal Medicine
Holden Chair of Cancer Biology
University of Iowa
Topic: Multiple Personalities for TRAFs in Immune Regulation
12 pm WRB 1-413

CFAR Leaders in AIDS Seminar
Greg Jonsson, MD
Staff Psychiatrist, Luthando HIV Clinic
Chris Hani Baragwanath Hospital, Soweto, South Africa
Topic: Luthando Neuropsychiatric HIV clinic: A View From a Fighter on the Front Lines of the Ever Changing HIV Epidemic in South Africa
12 pm SOM W203

January 25

Hematology and Oncology Division Research Conference
Smitha Krishnamurthi, MD
Assistant Professor, Div. of Hem/Onc
Topic: New Treatment Strategies for the Treatment of Pancreatic Cancer
8 am Lerner Tower B-151

Genomics Informational Tour
Patrick Leahy, PhD
Assistant Professor, Div. of General Medical Sciences-Oncology
Nicholas Beckloff, PhD
Instructor, Genetics
Topic: Sequencing Services at Case-UH
1 pm SOM W203

January 26

Molecular Biology and Microbiology Seminar
Scott Sieg, PhD
Associate Professor, AIDS Clinical Trial Unit
Topic: Interleukin-7 Unresponsiveness in HIV Disease: Are T Cells Stressed Out?
Anthony Lioi
Sieg Lab, Molecular Biology and Microbiology
Topic: Monocyte Activation and Membrane Disruption Mediated by hBD-3
1 pm SOM W203

NCRM Monthly Seminar
Stan Gerson, MD
Director, NCRM
Director, Case CCC
Professor, Medicine- Hem/Onc
Topic: NCRM in 2012: Focus on Clinical Applications
1 pm WRB 2-136

January 27

Hem/Onc Fellows Conference
Brad Clifford, MD 
Fellow, Div. of Hem/Onc
Topic: Genetic Abnormalities of the EGFR Pathway in African-American Patients with Non-small Cell Lung Cancer
8 am Wearn 137

Taussig Cancer Institute Grand Rounds
Christopher Sweeney, MBBS
Associate Professor, Medicine
Harvard University/Dana Farber Cancer Institute
Topic: Treating Hormone Sensitive Metastatic Prostate Cancer- Where to Next?
8 am R3/002-003 Cleveland Clinic

Cell Biology Seminar Series
Alan Zhu, PhD
Assistant Professor, Cell Biology, Genetics
CWRU/Cleveland Clinic
Topic: Posttranslational and Epigenetic Regulation of Hedgehog and Notch Signaling in Development
10 am NC1-202 Cleveland Clinic

Cancer Center Seminar Series
Michael R. Grever, MD
Professor and Chair, Internal Medicine
Professor, Pharmacology
The Ohio State University
Topic: Experimental Therapeutics: The Chronic B-Cell Leukemias
12 pm BRB 105

Cancer Center Research in Progress Seminar
Marvin Nieman, PhD
Assistant Professor, Medicine- Hem/Onc
Topic: Modulation of Protease Activated Receptor Signaling by Receptor Crosstalk
4 pm WRB 3-316

Case CCC Calendar

LRI Calendar


Pathology Research Seminar
January 30
Jonathan Chernoff, MD, PhD
Chief Scientific Officer
Fox Chase Cancer Center
Topic: p21-Activated Kinases as Anti-Cancer Targets
12 pm WRB 1-413

Cancer Cell Signaling Program Retreat
February 29
6-8 at the College Club
RSVP to Tracy Rehl at


Department of Biomedical Engineering Special Seminar
May 3
Steve Zullo, PhD
Program Director, Division of Discovery Science and Technology
National Institute of Biomedical Imaging and Bioengineering, NIH
Topic: NIH Grant Machine Revealed, Not a Black Box Anymore
12 pm Wickenden 509

NCI Second Symposium on Translational Genomics
March 15-16
NIH, Bethesda, Maryland


Children's Tumor Foundation Young Investigator Award Program
Pre-Application Deadline: January 27
Application Deadline: April 2

National Center for Research Resources (NCRR) Shared Instrumentation Grant (SIG) Program
Internal LOI Deadline: January 27
External Deadline: March 21

Sarcoma Foundation of America (SFA)
Deadline: January 31

2012 Lasker Awards
Deadline: February 1

ASCO Conquer Cancer Foundation Merit Awards
Deadline: February 1

Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research
Deadline Extended: February 1

Fight Colorectal Cancer-AACR Career Development Award, in memory of Lisa Dubow
Deadline Extended: February 1

Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research
Deadline Extended: February 1

Landon Foundation-AACR INNOVATOR Award for Research in Personalized Cancer Medicine 
Deadline Extended: February 1

Oncology Nursing Foundation
Deadline: February 1

Lymphatic Research Foundation (LRF) Additional Support for NIH-funded F32 Postdoctoral Fellows
Deadline: February 3

Innovations for Health: Solutions that Cross Borders
Deadline: February 13

Advancing Health Services through System Modeling Research
Deadline: February 15

Leukemia Research Foundation New Investigator Grants
Deadline: February 15

Ohio Cancer Research Associates
Deadline: February 17

Robert Wood Johnson Foundation Clinical Scholars Program
Deadline: February 29

Leukemia & Lymphoma Society Translational Research Program
LOI Deadline: March 1
Full Application Deadline: March 15

Childhood Brain Tumor Foundation (CBTF)
Deadline: March 12

James S. McDonnell Foundation 21st Century Research Awards
Deadline: March 14

Damon Runyon-Sohn Pediatric Cancer Fellowship Award
Deadline: March 15

American Legacy Foundation Sybil G. Jacobs Award for Outstanding Use of Tobacco Industry Documents
Deadline: March 23

American Legacy Foundation Christine O. Gregoire Youth/Young Adult Award for Outstanding Use of Tobacco Industry Documents
Deadline: March 23

Irvington Institute Fellowship Program
Deadline: April 1

Wendy Will Case Cancer Fund
Deadline: April 1

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

Case CCC Protocol Specific Research Support (PSRS)
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program
Application Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open

NIH BULLETIN – Notices and Funding Opportunities

Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01)(PA-12-082)

Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R21)(PA-12-083)

Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2012 (NOT-OD-12-033)

Notice of Legislative Mandates in Effect for FY2012 (NOT-OD-12-034)

Notice of Salary Limitation on Grants, Cooperative Agreements, and Contracts (NOT-OD-12-035)

NIH Fiscal Policy for Grant Awards FY 2012 (NOT-OD-12-036)

Administrative Supplements to NIH-funded Program Projects/Center Grants: Research Relevant to the Family Smoking Prevention and Tobacco Control Act (NOT-CA-12-007)

Participation of NICHD in PAR-12-010 (R01) and PAR-12-011 (U01), NIH Competitive Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (NOT-HD-12-010)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax


If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to